Risks and benefits of combining denosumab and surgery in giant cell tumor of bone—a case series

BACKGROUND: The RANK ligand inhibitor denosumab is being investigated for treatment of giant cell tumor of bone, but the available data in the literature remains sparse and controversial. This study analyzes the results of combining denosumab with surgical treatment and highlights possible changes f...

Descripción completa

Detalles Bibliográficos
Autores principales: Müller, Daniel A., Beltrami, Giovanni, Scoccianti, Guido, Campanacci, Domenico A., Franchi, Alessandro, Capanna, Rodolfo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095954/
https://www.ncbi.nlm.nih.gov/pubmed/27809843
http://dx.doi.org/10.1186/s12957-016-1034-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095954/
https://www.ncbi.nlm.nih.gov/pubmed/27809843
http://dx.doi.org/10.1186/s12957-016-1034-y

Ejemplares similares